Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis - Journal of Neurology
Source : https://link.springer.com/article/10.1007/s00415-023-11617-1
Introduction The terminal complement C5 inhibitor ravulizumab has a long elimination half-life, allowing maintenance dosing every 8 weeks. In the 26-week, double-blind, randomized, placebo-controlled period (RCP) of the CHAMPION MG...
Conclusions: PK/PD evidence supports the use of ravulizumab every 8 weeks for immediate, complete, and sustained inhibition of terminal complement C5 in adults with AChR Ab+ gMG.
Conclusions/Relevance: While the landscape for treatment of generalized MG has expanded over recent years, there is still an unmet need for patients for whom multiple lines of treatment have failed. The introduction of neonatal Fc receptor antagonists such as efgartigimod alfa may have an immediate impact in patients for whom standard-of-care...
The determinants of expert opinion in the development of care pathways: insights from an exploratory cluster analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36869326/
These findings might indicate a poor ability of the expert to discriminate what is not appropriate from what is not complete. Also, the opinion of the expert might be influenced...
Conclusions: These findings might indicate a poor ability of the expert to discriminate what is not appropriate from what is not complete. Also, the opinion of the expert might be influenced by the working setting, but not by the experience in NMD (as measured in years).
Short-term outcome prediction for myasthenia gravis: an explainable machine learning model - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36860354/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The explainable, ML-based predictive model can aid in forecasting the short-term outcome for MG with good accuracy in clinical practice.
"
Landscape analysis of m6A modification regulators related biological functions and immune characteristics in myasthenia gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36864526/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Our findings suggested that m6A RNA modification had an important effect on immunity molecular mechanism of MG and provided a new perspective into understanding the pathogenesis of MG.